A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

NCT02315534 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: BBI608
DRUG: Temozolomide

Sponsor

Sumitomo Pharma America, Inc.